Chokri Ben Lamine/LinkedIn
Jun 12, 2026, 16:14
Chokri Ben Lamine: EHA26 – SCD Curative Therapy Pathway
Chokri Ben Lamine, Assistant Consultant at King Faisal Specialist Hospital and Research Center, shared a post on X:
“EHA26 – SCD Curative Therapy Pathway
EHA-SWG and EBMT-HWP joint recommendations highlight who should be considered for:
- Allogeneic HCT
- Cell and gene therapy
in sickle cell disease
Key clinical logic:
- Confirm HbSS and severe HbSβ⁰ genotype
- Assess for severe clinical presentation
- If HLA-matched family donor is available, proceed to allo-HCT assessment
- If no matched donor is available and eligibility criteria are met, assess for gene therapy at a transplant center.
Practical message:
Curative therapy in SCD is becoming algorithm-driven, but still needs expert individualized review:
- genotype
- disease severity
- donor availability
- age r
- egulatory and scientific updates
- patient-centered risk–benefit discussion
Session: Optimising the transplant process in haemoglobinopathies
Chair: Ben Carpenter”
Other posts featuring Chokri Ben Lamine on Hemostasis Today.
-
Jun 12, 2026, 16:40Connie Montgomery about Last Night with Trialport and Global Genes
-
Jun 12, 2026, 16:20Tejas Ahire: When the Body’s Clotting System Goes Out of Control
-
Jun 12, 2026, 16:13Talha Badar: Excellent Talk by Francesca Palandri on ET and PV at EHA 2026
-
Jun 12, 2026, 16:12Miguel Gómez Álvarez: The Evidence on Disease Burden in PNH
-
Jun 12, 2026, 16:11Shinya Goto: The Japanese Investigators Behind Tranexamic Acid
-
Jun 12, 2026, 16:10Rahul Kumar: Improved Chemotherapy Delivery Is Meaningful Only When It Improves Patient Outcomes
-
Jun 12, 2026, 15:24A Practical Guide to Living Well with ITP – ITP Support Association
-
Jun 12, 2026, 15:16Courtney Lawrence: The AABB Bulletin on Neonatal Red Blood Cell Transfusion and Mannitol Exposure is Now Released
-
Jun 12, 2026, 15:05Sukanto Paul: Therapeutic Plasma Exchange as an Extracorporeal Liver Support Therapy